	<b>M07.5 - LORAZEPAM (ATIVAN)</b>	
	Version date: 2025-02-04	Effective date: 2025-04-30 (07:00)



INDICATIONS
<ul style="list-style-type: none"> <li>Severe anxiety or agitation that is interfering with, or may interfere with, the management and safe transport of the patient</li> </ul>

WARNINGS
<b>ABSOLUTE CONTRAINDICATIONS:</b> <ul style="list-style-type: none"> <li>Hypersensitivity to lorazepam</li> <li>Hypotension / hypoperfusion / shock</li> <li>Respiratory depression</li> <li>Central nervous system depression</li> </ul>

ADMINISTRATION	
ORAL / SUBLINGUAL	PCP / ICP / ACP
<b>ADULTS:</b> <ul style="list-style-type: none"><li>• 1 to 2 mg</li><li>• Repeat once in 15 to 30 minutes if required</li></ul> <b>ADOLESCENTS:</b> <ul style="list-style-type: none"><li>• 1 mg</li><li>• Repeat once in 15 to 30 minutes if required</li></ul>	

LINKS
<ul style="list-style-type: none"> <li>E02 - Agitation</li> </ul>

NOTES
<ol style="list-style-type: none"> <li>Benzodiazepines may have more pronounced respiratory and central nervous system effects in the elderly, especially if frail or compromised. Consider the lower dose in patients over 75 years of age.</li> </ol>

APPROVED BY	
	
Provincial Medical Director	Provincial Associate Medical Director

VERSION CHANGES (refer to X08 for change tracking)
<ul style="list-style-type: none"><li>• Addition of advanced work scope</li></ul>